| Code | CSB-RA011671MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to ABX-IL8, targeting CXCL8 (interleukin-8), a potent pro-inflammatory chemokine that plays a central role in innate immune responses. CXCL8 functions as a powerful chemoattractant and activator of neutrophils, directing their migration to sites of infection or tissue injury through interaction with CXCR1 and CXCR2 receptors. Dysregulated CXCL8 expression is implicated in numerous pathological conditions, including acute respiratory distress syndrome, chronic inflammatory diseases, sepsis, and various malignancies where it promotes tumor angiogenesis, metastasis, and immune evasion.
ABX-IL8, the reference antibody, is a fully humanized IgG2 monoclonal antibody that neutralizes CXCL8 activity by preventing its binding to cell surface receptors. This biosimilar provides researchers with a valuable tool for investigating CXCL8-mediated inflammatory pathways, studying neutrophil biology, and exploring therapeutic strategies for inflammation-driven diseases and cancer. The antibody enables functional studies examining CXCL8's role in immune cell recruitment, cytokine networks, and disease progression across diverse experimental models.
There are currently no reviews for this product.